Table 3.
Baseline characteristics, as well as parameters before and 6 months after initiation of metreleptin treatment in LD patients (n = 16). Abbreviations are indicated in Table 1. Values for median (interquartile range) or absolute numbers (n) are shown. * indicates p < 0.05 as assessed by Wilcoxon signed rank test.
| Parameter | Baseline Characteristics | ||
|---|---|---|---|
| n | 16 | ||
| Age (years) | 42 (18) | ||
| Gender (male/female) | 3/13 | ||
| Before treatment | 6 months treatment | p | |
| GDF15 (ng/L) | 1312.0 (1277.1) | 1157.6 (888.0) | 0.715 |
| BMI (kg/m2) | 27.4 (5.6) | 27.3 (7.1) | 0.035 * |
| WHR | 0.97 (0.11) | 0.96 (0.09) | 0.331 |
| SBP (mmHg) | 128 (16) | 128 (9) | 0.754 |
| DBP (mmHg) | 80 (16) | 74 (14) | 0.510 |
| HbA1c (%) | 8.0 (2.2) | 7.2 (1.3) | 0.081 |
| HbA1c (mmol/mol) | 63.9 (23.8) | 55.3 (14.5) | 0.119 |
| FG (mmol/L) | 9.6 (2.9) | 7.9 (4.2) | 0.808 |
| FI (pmol/L) | 144.2 (280.0) | 238.1 (374.4) | 0.542 |
| HOMA-IR | 12.4 (11.0) | 10.6 (22.2) | 0.583 |
| Cholesterol (mmol/L) | 5.85 (4.94) | 5.11 (4.32) | 0.502 |
| HDL cholesterol (mmol/L) | 0.62 (0.48) | 0.62 (0.42) | 0.659 |
| LDL cholesterol (mmol/L) | 1.65 (2.09) | 1.66 (1.79) | 0.318 |
| TG (mmol/L) | 8.64 (14.78) | 3.97 (6.18) | 0.020 * |
| FFA (mmol/L) | 0.70 (0.30) | 0.63 (0.42) | 0.594 |
| Creatinine (µmol/L) | 63 (20) | 62 (25) | 1.000 |
| eGFR (mL/min/1.73 m2) | 101.3 (41.1) | 109.3 (33.4) | 0.893 |
| CRP (mg/L) | 3.1 (5.4) | 4.5 (4.5) | 0.094 |
| Adiponectin (mg/L) | 2.2 (1.8) | 2.0 (2.1) | 0.382 |
| Leptin (µg/L) | 5.1 (4.6) | 11.8 (20.6) | 0.023 * |
| ALAT (µkat/L) | 0.54 (0.46) | 0.52 (0.33) | 0.055 |
| ASAT (µkat/L) | 0.57 (0.57) | 0.47 (0.52) | 0.680 |
| GGT (µkat/L) | 1.04 (2.53) | 0.91 (0.74) | 0.194 |